#Ulcerative_Colitis
LightNews LightNews
newsen.bsky.social
Accro Bioscience Begins Phase IIb Trials for Promising UC Treatment AC-101#USA#New_York#Ulcerative_Colitis#AC-101#Accro_Bioscience
Accro Bioscience Begins Phase IIb Trials for Promising UC Treatment AC-101
Accro Bioscience has initiated its Phase IIb clinical trial for AC-101, a selective RIPK2 inhibitor aimed at treating moderate-to-severe ulcerative colitis, marking a significant milestone.
third-news.com
September 20, 2026 at 10:13 AM
newsen.bsky.social
Understanding Inflammatory Bowel Disease: Symptoms, Diagnosis, and Treatment Options#United_States#Ulcerative_Colitis#Crohn's_Disease#Mission#IBD
Understanding Inflammatory Bowel Disease: Symptoms, Diagnosis, and Treatment Options
Inflammatory bowel disease (IBD) affects millions. Understand its symptoms, diagnostic processes, and potential treatments in this comprehensive guide.
third-news.com
December 16, 2024 at 5:35 PM
newsen.bsky.social
Accro Bioscience to Unveil Promising Phase Ib AC-101 Data at UEG Week 2026 in Barcelona#Spain#Ulcerative_Colitis#Barcelona#AC-101#Accro_Bioscience
Accro Bioscience to Unveil Promising Phase Ib AC-101 Data at UEG Week 2026 in Barcelona
Accro Bioscience will present vital Phase Ib data for AC-101, a selective RIPK2 inhibitor aimed at treating moderate-to-severe ulcerative colitis, at UEG Week 2026.
third-news.com
August 13, 2026 at 11:11 AM
newsen.bsky.social
First Lawsuit Against Chipotle Over Salmonella Outbreak: A Case of Food Safety Gone Wrong#United_States#Chipotle#Ulcerative_Colitis#Bozeman#Salmonella
First Lawsuit Against Chipotle Over Salmonella Outbreak: A Case of Food Safety Gone Wrong
A lawsuit filed against Chipotle claims a Salmonella outbreak linked to jalapeños left a teenager with ulcerative colitis. This case highlights crucial food safety issues.
third-news.com
August 5, 2026 at 9:50 PM
newsen.bsky.social
Inflammatory Bowel Disease Market Poised for Significant Growth Through 2036 with Next-gen Therapies#United_States#Ulcerative_Colitis#Las_Vegas#Inflammatory_Bowel_Disease#Crohn's_Disease
Inflammatory Bowel Disease Market Poised for Significant Growth Through 2036 with Next-gen Therapies
The inflammatory bowel disease market is set to experience considerable expansion driven by innovative therapies and rising patient prevalence. Explore upcoming trends and key players shaping this landscape.
third-news.com
July 30, 2026 at 2:43 PM
r-meditation.at.shendrick.net
Ulcerative colitis https://old.reddit.com/r/Meditation/comments/1o4jyz4/ulcerative_colitis/

#meditation
October 12, 2025 at 8:56 AM
newsen.bsky.social
Johnson & Johnson's New Co-Antibody JNJ-4804 Shows Promising Results for Inflammatory Bowel Disease Treatment#United_States#Chicago#Ulcerative_Colitis#Crohn's_Disease#JNJ-4804
Johnson & Johnson's New Co-Antibody JNJ-4804 Shows Promising Results for Inflammatory Bowel Disease Treatment
Johnson & Johnson announces promising Phase 2b results for their co-antibody therapy JNJ-4804, targeting stubborn inflammatory bowel diseases.
third-news.com
May 5, 2026 at 12:08 PM
newsen.bsky.social
Lilly's Omvoh Demonstrates Long-Term Efficacy in Ulcerative Colitis Treatment with Remarkable Results#United_States#Indianapolis#Ulcerative_Colitis#Eli_Lilly#Omvoh
Lilly's Omvoh Demonstrates Long-Term Efficacy in Ulcerative Colitis Treatment with Remarkable Results
Eli Lilly's Omvoh shows significant long-term efficacy in patients with ulcerative colitis, achieving sustained disease clearance over four years.
third-news.com
May 5, 2026 at 10:52 AM
newsen.bsky.social
Earendil Labs Marks Milestone with First Patient Doses in IBD Treatment Trial#USA#Ulcerative_Colitis#Wilmington#Earendil_Labs#HXN-1001
Earendil Labs Marks Milestone with First Patient Doses in IBD Treatment Trial
Earendil Labs has begun its Phase IIa trial for HXN-1001 in ulcerative colitis patients, a major step towards innovative IBD treatments.
third-news.com
April 2, 2026 at 11:12 AM
newsen.bsky.social
Evinature's Innovative CurQD Selected for Military-Funded Ulcerative Colitis Study#USA#New_York#Ulcerative_Colitis#Evinature#CurQD
Evinature's Innovative CurQD Selected for Military-Funded Ulcerative Colitis Study
Evinature's CurQD has been chosen for a pivotal U.S. Department of Defense clinical trial aimed at improving ulcerative colitis treatment through a combined approach.
third-news.com
March 18, 2026 at 6:02 PM
newsen.bsky.social
Ulcerative Colitis Market Set for Robust Growth with New Therapies and Biologics by 2034#USA#Ulcerative_Colitis#Las_Vegas#Biologics#Novel_Therapies
Ulcerative Colitis Market Set for Robust Growth with New Therapies and Biologics by 2034
The ulcerative colitis market is on the rise due to increased disease prevalence and innovative therapies. Anticipated drug launches are set to drive market expansion through 2034.
third-news.com
December 17, 2025 at 10:43 PM
newsen.bsky.social
Eli Lilly's Omvoh Receives FDA Approval for Simplified Ulcerative Colitis Treatment#United_States#Indianapolis#Ulcerative_Colitis#Eli_Lilly#Omvoh
Eli Lilly's Omvoh Receives FDA Approval for Simplified Ulcerative Colitis Treatment
Eli Lilly has announced that the FDA has approved Omvoh, a single-injection maintenance treatment for adults with ulcerative colitis, enhancing their quality of life with easier management.
third-news.com
October 27, 2025 at 8:19 PM
newsen.bsky.social
Icotrokinra Shows Promising Results in Treating Ulcerative Colitis Over 28 Weeks#United_States#Ulcerative_Colitis#Johnson_&_Johnson#Phoenix#Icotrokinra
Icotrokinra Shows Promising Results in Treating Ulcerative Colitis Over 28 Weeks
Icotrokinra, a novel oral therapy, has shown significant efficacy in patients with ulcerative colitis, sustaining treatment benefits through 28 weeks of use.
third-news.com
October 27, 2025 at 11:40 AM
newsen.bsky.social
Lilly's Omvoh Shows Promising Results in Managing Bowel Urgency for Ulcerative Colitis Patients#USA#Indianapolis#Ulcerative_Colitis#Omvoh#Lilly
Lilly's Omvoh Shows Promising Results in Managing Bowel Urgency for Ulcerative Colitis Patients
Eli Lilly's Phase 3b LUCENT-URGE study reveals significant improvements in bowel urgency for ulcerative colitis patients receiving Omvoh, enhancing their quality of life.
third-news.com
October 27, 2025 at 10:55 AM
newsen.bsky.social
Cristcot Unveils Promising Findings on Innovative Ulcerative Colitis Therapy at ACG 2025#USA#Austin#Ulcerative_Colitis#Cristcot#HCA_Therapy
Cristcot Unveils Promising Findings on Innovative Ulcerative Colitis Therapy at ACG 2025
Cristcot reveals pivotal clinical findings on their new ulcerative colitis treatment at the ACG 2025 Annual Meeting, showcasing significant efficacy.
third-news.com
October 26, 2025 at 7:07 PM
newsen.bsky.social
Loopback Analytics Takes Home Attendee Choice Poster Award at NASP Annual Meeting#USA#Dallas#Ulcerative_Colitis#Loopback_Analytics#NASP_Annual_Meeting
Loopback Analytics Takes Home Attendee Choice Poster Award at NASP Annual Meeting
Loopback Analytics recently won the Attendee Choice Poster Award at the NASP Annual Meeting for their research on ulcerative colitis. The study focuses on standardized disease assessment approaches.
third-news.com
October 7, 2025 at 12:36 PM
newsen.bsky.social
Icotrokinra: A Promising New Treatment for Ulcerative Colitis#United_States#Ulcerative_Colitis#Johnson_&_Johnson#Spring_House#Icotrokinra
Icotrokinra: A Promising New Treatment for Ulcerative Colitis
Icotrokinra demonstrates significant therapeutic benefits and safety for ulcerative colitis patients, as seen in recent clinical trials. The once-daily pill showed impressive clinical response rates and remission improvements.
third-news.com
October 7, 2025 at 12:18 PM
newsen.bsky.social
TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results#USA#Ulcerative_Colitis#TREMFYA®#Spring_House#guselkumab
TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results
TREMFYA® (guselkumab) emerges as the first IL-23 inhibitor with a fully subcutaneous regimen, showing remarkable results in ulcerative colitis treatment over 48 weeks.
third-news.com
October 7, 2025 at 12:16 PM
newsen.bsky.social
Eli Lilly's Omvoh: A Game-Changer in Ulcerative Colitis Treatment with Four-Year Efficacy#United_States#Indianapolis#Ulcerative_Colitis#Eli_Lilly#Omvoh
Eli Lilly's Omvoh: A Game-Changer in Ulcerative Colitis Treatment with Four-Year Efficacy
Eli Lilly's Omvoh (mirikizumab-mrkz) offers sustained clinical remission in ulcerative colitis over four years without steroids, marking a significant advancement in treatment options.
third-news.com
October 7, 2025 at 10:53 AM
newsen.bsky.social
TREMFYA® Gains FDA Approval for Subcutaneous Induction in Ulcerative Colitis Treatment#United_States#Ulcerative_Colitis#TREMFYA#Horsham#guselkumab
TREMFYA® Gains FDA Approval for Subcutaneous Induction in Ulcerative Colitis Treatment
Johnson & Johnson's TREMFYA® becomes the first and only fully subcutaneous IL-23 inhibitor, now approved for adult ulcerative colitis treatment.
third-news.com
September 19, 2025 at 9:38 PM
newsen.bsky.social
Study Reveals Sharp Increase in Ulcerative Colitis and Crohn’s Disease Patients in Japan#Japan#Ulcerative_Colitis#Tokyo#Crohn's_Disease#Japan_Research
Study Reveals Sharp Increase in Ulcerative Colitis and Crohn’s Disease Patients in Japan
A recent study indicates that the number of ulcerative colitis and Crohn's disease patients in Japan has risen significantly, suggesting a need for improved healthcare policies.
third-news.com
September 19, 2025 at 4:40 AM
newsen.bsky.social
Cristcot's Major Engagement at the 2025 GI ReConnect Annual Meeting: A Leap Forward in Gastroenterology#USA#Ulcerative_Colitis#Cristcot#GI_ReConnect#Aurora,_Colorado
Cristcot's Major Engagement at the 2025 GI ReConnect Annual Meeting: A Leap Forward in Gastroenterology
Cristcot showcased its commitment to gastrointestinal health by actively participating in the 2025 GI ReConnect meeting, emphasizing advancements in ulcerative colitis treatment.
third-news.com
June 24, 2025 at 11:14 AM
newsen.bsky.social
Cristcot Hires Richard Kim as CCO to Drive Commercialization Strategy for New Treatments#USA#Ulcerative_Colitis#Concord#Cristcot#Richard_Kim
Cristcot Hires Richard Kim as CCO to Drive Commercialization Strategy for New Treatments
Richard Kim has been appointed Chief Commercial Officer at Cristcot, leading efforts to bring innovative therapies for gastrointestinal diseases to market.
third-news.com
June 10, 2025 at 11:20 AM
newsen.bsky.social
Tremfya®: A New Treatment for Ulcerative Colitis Launched in Japan#Japan#Ulcerative_Colitis#TREMFYA®#Johnson_&_Johnson#Tokyo
Tremfya®: A New Treatment for Ulcerative Colitis Launched in Japan
Tremfya®, an innovative dual-acting treatment for ulcerative colitis, is now available in Japan, offering hope to patients seeking remission.
third-news.com
May 21, 2025 at 1:21 AM
newsen.bsky.social
Tremfya® Maintains Long-Term Clinical and Endoscopic Remission in Ulcerative Colitis Patients#USA#San_Diego#Ulcerative_Colitis#Johnson_&_Johnson#TREMFYA
Tremfya® Maintains Long-Term Clinical and Endoscopic Remission in Ulcerative Colitis Patients
Latest data from Johnson & Johnson highlights Tremfya®'s efficacy in maintaining long-term remission in ulcerative colitis patients over 92 weeks, showcasing promising clinical outcomes.
third-news.com
May 20, 2025 at 6:27 AM